New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance

Natali Pflug, Paula Cramer, Sandra Robrecht, Jasmin Bahlo, Anne Westermann, Anna-Maria Fink, Alexandra Schrader, Petra Mayer, Sebastian Oberbeck, Till Seiler, Thorsten Zenz, Jan Dürig, Karl-Anton Kreuzer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Marco Herling, Georg Hopfinger

Open source

DOI: 10.1080/10428194.2018.1488253
Published: 2018-09-20
Container: Leukemia & Lymphoma
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/10428194.2018.1488253,
  title = {New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance},
  author = {Natali Pflug and Paula Cramer and Sandra Robrecht and Jasmin Bahlo and Anne Westermann and Anna-Maria Fink and Alexandra Schrader and Petra Mayer and Sebastian Oberbeck and Till Seiler and Thorsten Zenz and Jan Dürig and Karl-Anton Kreuzer and Stephan Stilgenbauer and Barbara Eichhorst and Michael Hallek and Marco Herling and Georg Hopfinger},
  year = {2018},
  journal = {Leukemia \&amp; Lymphoma},
  doi = {10.1080/10428194.2018.1488253},
  url = {https://doi.org/10.1080/10428194.2018.1488253}
}

RIS

TY  - JOUR
TI  - New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance
AU  - Natali Pflug
AU  - Paula Cramer
AU  - Sandra Robrecht
AU  - Jasmin Bahlo
AU  - Anne Westermann
AU  - Anna-Maria Fink
AU  - Alexandra Schrader
AU  - Petra Mayer
AU  - Sebastian Oberbeck
AU  - Till Seiler
AU  - Thorsten Zenz
AU  - Jan Dürig
AU  - Karl-Anton Kreuzer
AU  - Stephan Stilgenbauer
AU  - Barbara Eichhorst
AU  - Michael Hallek
AU  - Marco Herling
AU  - Georg Hopfinger
PY  - 2018
JO  - Leukemia &amp; Lymphoma
DO  - 10.1080/10428194.2018.1488253
UR  - https://doi.org/10.1080/10428194.2018.1488253
ER  -

APA

Pflug, N., Cramer, P., Robrecht, S., Bahlo, J., Westermann, A., Fink, A., Schrader, A., Mayer, P., Oberbeck, S., Seiler, T., Zenz, T., Dürig, J., Kreuzer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M., Herling, M., & Hopfinger, G. (2018). New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance. Leukemia & Lymphoma. https://doi.org/10.1080/10428194.2018.1488253

Source records

crossref · retrieved 2026-09-27T11:03:56.092Z